Population characteristics
| Characteristic . | n (%) or median [IQR] . | Missing (%) . | Included in* . |
|---|---|---|---|
| Age, y | 55 [40, 64] | 0 (0) | C-A, EBMT, PAM, rPAM, C-E |
| Days from diagnosis to HSCT | 189 [104, 596] | 17 (3.2) | EBMT, C-E |
| Diagnosis | 0 (0) | EBMT, PAM, rPAM, C-E, rDRI | |
| AML | 233 (44.1) | ||
| ALL | 52 (9.8) | ||
| CLL | 11 (2.1) | ||
| CML | 14 (2.7) | ||
| HL | 19 (3.6) | ||
| MDS | 78 (14.8) | ||
| MM | 20 (3.8) | ||
| MF | 20 (3.8) | ||
| NHL | 65 (12.3) | ||
| AA/nonmalignant | 16 (3.0) | ||
| Serum ALT, U/L | 32 [18, 53] | 0 (0) | HCT-CI, C-A, PAM, C-E |
| Serum creatinine, mg/dL | 0.85 [0.73, 1.03] | 0 (0) | HCT-CI, C-A, PAM, EASIx, C-E |
| Serum LDH, U/L | 208 [173, 276] | 0 (0) | EASIx |
| Platelets, ×109/L | 132 [64, 190] | 0 (0) | EASIx |
| FEV1, % expected | 95 [84, 104] | 0 (0) | HCT-CI, C-A, PAM, rPAM, C-E |
| DLCo, adjusted for Hb | 92.9 [80.4, 109.1] | 0 (0) | HCT-CI, C-A, C-E |
| Disease risk | 0 (0) | rPAM,† rDRI | |
| Low risk | 29 (5.5) | ||
| Intermediate risk | 298 (56.4) | ||
| High risk | 144 (27.3) | ||
| Very high risk | 39 (7.4) | ||
| Not applicable | 18 (3.4) | ||
| Regimen intensity | 0 (0) | ||
| Myeloablative | 391 (74.1) | ||
| Reduced intensity | 137 (25.9) | ||
| TBI-containing regimen | 54 (10.2) | 0 (0) | PAM |
| Donor | 0 (0) | EBMT, PAM, rPAM, C-E | |
| Matched sibling | 241 (45.6) | ||
| Matched unrelated, 10/10 | 207 (39.2) | ||
| Mismatched unrelated, 9/10 | 80 (15.2) | ||
| Female to male | 126 (23.9) | 0 (0) | EBMT |
| CMV serostatus pair, % | 38 (7.2) | rPAM | |
| Donor − Recipient − | 52 (9.8) | ||
| Donor − Recipient + | 96 (18.2) | ||
| Donor + Recipient − | 30 (5.7) | ||
| Donor + Recipient + | 312 (59.1) |
| Characteristic . | n (%) or median [IQR] . | Missing (%) . | Included in* . |
|---|---|---|---|
| Age, y | 55 [40, 64] | 0 (0) | C-A, EBMT, PAM, rPAM, C-E |
| Days from diagnosis to HSCT | 189 [104, 596] | 17 (3.2) | EBMT, C-E |
| Diagnosis | 0 (0) | EBMT, PAM, rPAM, C-E, rDRI | |
| AML | 233 (44.1) | ||
| ALL | 52 (9.8) | ||
| CLL | 11 (2.1) | ||
| CML | 14 (2.7) | ||
| HL | 19 (3.6) | ||
| MDS | 78 (14.8) | ||
| MM | 20 (3.8) | ||
| MF | 20 (3.8) | ||
| NHL | 65 (12.3) | ||
| AA/nonmalignant | 16 (3.0) | ||
| Serum ALT, U/L | 32 [18, 53] | 0 (0) | HCT-CI, C-A, PAM, C-E |
| Serum creatinine, mg/dL | 0.85 [0.73, 1.03] | 0 (0) | HCT-CI, C-A, PAM, EASIx, C-E |
| Serum LDH, U/L | 208 [173, 276] | 0 (0) | EASIx |
| Platelets, ×109/L | 132 [64, 190] | 0 (0) | EASIx |
| FEV1, % expected | 95 [84, 104] | 0 (0) | HCT-CI, C-A, PAM, rPAM, C-E |
| DLCo, adjusted for Hb | 92.9 [80.4, 109.1] | 0 (0) | HCT-CI, C-A, C-E |
| Disease risk | 0 (0) | rPAM,† rDRI | |
| Low risk | 29 (5.5) | ||
| Intermediate risk | 298 (56.4) | ||
| High risk | 144 (27.3) | ||
| Very high risk | 39 (7.4) | ||
| Not applicable | 18 (3.4) | ||
| Regimen intensity | 0 (0) | ||
| Myeloablative | 391 (74.1) | ||
| Reduced intensity | 137 (25.9) | ||
| TBI-containing regimen | 54 (10.2) | 0 (0) | PAM |
| Donor | 0 (0) | EBMT, PAM, rPAM, C-E | |
| Matched sibling | 241 (45.6) | ||
| Matched unrelated, 10/10 | 207 (39.2) | ||
| Mismatched unrelated, 9/10 | 80 (15.2) | ||
| Female to male | 126 (23.9) | 0 (0) | EBMT |
| CMV serostatus pair, % | 38 (7.2) | rPAM | |
| Donor − Recipient − | 52 (9.8) | ||
| Donor − Recipient + | 96 (18.2) | ||
| Donor + Recipient − | 30 (5.7) | ||
| Donor + Recipient + | 312 (59.1) |
AA, aplastic anemia; ALL, acute lymphoid leukemia; ALT, alanine aminotransferase; AML, acute myeloid leukemia; C-A, comorbidity-age; C-E, comorbidity-EBMT; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; DLCo, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; HL, Hodgkin lymphoma; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; TBI, total body irradiation.
Additional comorbidity variables are included in the HCT-CI and C-A scores.
As defined by the rDRI.11 Alternative disease-staging schemes are included in the EBMT and PAM scores.